Indivior

Indivior PLC is a global pharmaceutical company dedicated to treating opioid use disorder (OUD) and related conditions. Established in December 2014 as a spin-off from Reckitt Benckiser Group PLC, Indivior is publicly traded on the London Stock Exchange. The company aims to address the opioid crisis by providing access to evidence-based treatments that can significantly improve the lives of those affected. Indivior's core products include Suboxone, a combination of buprenorphine and naloxone, which has been a key revenue driver. Other offerings include Sublocade, a monthly injectable formulation of buprenorphine, and Opvee, a naloxone product for emergency overdose response. The company is also developing INDV-6001, a long-acting injectable formulation. Indivior engages with various stakeholders, including healthcare providers, government agencies, and patient advocacy groups, to promote awareness and education about addiction as a chronic disease.